Electronic Arts (NASDAQ:EA): Brean Capital pointed out that Electronic Arts beat its first quarter guidance, and believes that the quarter showed potential for accelerated earnings growth, margin expansion, and share price appreciation. Brean expects the naming of a new CEO to be a near-term catalyst, and rates the shares at Buy with a $29 price target.
Sarepta Therapeutics (NASDAQ:SRPT): Deutsche Bank says Wednesday’s news that Sarepta plans on filing for accelerated approval in the first half of 2014 is an upside surprise to investor expectations, but the firm expects some of the cautious comments in the release to limit share upside, pointing to a press release that states that the Food and Drug Administration is requesting more methodology and verification of dystrophin quantification. Deutsche has a Buy rating on the stock.
Schlumberger Ltd. (NYSE:SLB): Following Schlumberger’s higher-than-expected operating earnings per share, BMO Capital thinks that the company reported solid results and has the potential to generate 2014 EPS of $5.70. The firm raised its price target on the stock to $97 from $85 and keeps an Outperform rating on the shares.
Micron (NASDAQ:MU): Sterne Agee recommends buying Micron shares on market-related weakness and says that partner commentary has been bullish, pointing to stable 2014 DRAM trends.